1. Introduction
===============

Polycystic ovary syndrome (PCOS) is the most common gynecological endocrine disorder that is characterized by ovarian dysfunction, hyperandrogenism, and polycystic ovary morphology \[[@B1-ijms-16-02403]\]. It is associated with increased risks of infertility, impaired glucose tolerance, type 2 diabetes mellitus, and metabolic syndrome \[[@B2-ijms-16-02403]\]. While 6%--17% of reproductive-age women worldwide suffer PCOS \[[@B3-ijms-16-02403],[@B4-ijms-16-02403]\], some ethnicities, such as South Asian, have higher incidence rates \[[@B5-ijms-16-02403]\]. The exact molecular mechanism and cellular pathways underlying this disorder are still unclear. Etiological studies demonstrated the significance of genetic susceptibility for the pathogenesis of PCOS \[[@B6-ijms-16-02403]\]. It is believed that multiple, instead of single genes, such as fibrillin-3 (*FBN3*), fat and obesity associated gene (*FTO*), insulin (*INS*), insulin receptor (*INSR*), insulin receptor substrate 1 (*ISR1*), DENN/MADD domain containing 1A (*DENND1A*), thyroid adenoma associated protein (*THADA*), and luteinizing hormone receptor (*LHR*), may contribute to the development of PCOS \[[@B7-ijms-16-02403],[@B8-ijms-16-02403]\]. For example, *DENND1A* may alter the aminopeptidase activity of endoplasmic reticulum and is involved in the development of PCOS \[[@B9-ijms-16-02403]\].

*INSR* gene is located at the short arm of chromosome 19 and comprises 22 exons. The *Insr* knockout mice manifested extreme insulin resistance \[[@B10-ijms-16-02403]\]. Insulin resistance may up-regulate LH secretion in pituitary, testosterone production in theca cells, and P450scc activity in granulosa cells, which may disturb follicular maturation and lead to PCOS \[[@B7-ijms-16-02403]\]. Considering that accumulated data showed a strong association between *INSR* and insulin resistance \[[@B11-ijms-16-02403]\], allelic polymorphism of *INSR* may impose a genetic predisposition for the development of PCOS. Indeed, a series of studies have been conducted to investigate the relationship between single nucleotide polymorphisms (SNPs) of *INSR* and PCOS. However, data from these studies appeared to be highly controversial \[[@B12-ijms-16-02403],[@B13-ijms-16-02403]\]. Although a meta-analysis published in 2010 has reviewed then available data, and found no association between the SNPs of *INSR* and PCOS \[[@B14-ijms-16-02403]\], two Genome-Wide Association Studies in 2011 \[[@B15-ijms-16-02403]\] and 2012 \[[@B16-ijms-16-02403]\] pointed to a positive association between the polymorphisms of *INSR* and PCOS. These findings ignited a renewed interest in the topic. Since then more studies have been performed, and both positive and negative results have been reported.

As there have been plenty of studies exploring the role of *INSR* polymorphisms in PCOS, and the results often contradict each other, we carried out an updated meta-analysis covering recent data. The findings will provide useful information for elucidating the relationship between the polymorphisms of *INSR* and the risk of PCOS.

2. Results
==========

2.1. Selection of the Studies
-----------------------------

A total of 150 articles were recognized by database searching and reference reading ([Figure 1](#ijms-16-02403-f001){ref-type="fig"}), among which 85 studies were excluded based on information from titles and abstracts. Due to the exclusion reasons listed in the flow chart, including overlapping patient populations in three articles \[[@B17-ijms-16-02403],[@B18-ijms-16-02403],[@B19-ijms-16-02403]\], 20 studies remained for the qualitative synthesis. Eight studies were removed because the involved SNPs were detected in fewer than three studies \[[@B20-ijms-16-02403],[@B21-ijms-16-02403],[@B22-ijms-16-02403],[@B23-ijms-16-02403]\] or the failure to obtain original genotype data \[[@B15-ijms-16-02403],[@B16-ijms-16-02403],[@B24-ijms-16-02403],[@B25-ijms-16-02403]\]. 12 studies were finally selected for meta-analysis.

![Flow chart of study selection for meta-analysis of insulin receptor (*INSR*) single nucleotide polymorphisms (SNPs) and risk of polycystic ovarian syndrome (PCOS).](ijms-16-02403-g001){#ijms-16-02403-f001}

The initially included studies consist of 10 from Asia, seven from Europe, two from North America, and one from South America. These studies cover totally 17,460 cases and 23,845 controls ([Table 1](#ijms-16-02403-t001){ref-type="table"}). All of these studies were case-control studies published between 1994 and 2013. All were published in English except for one in Chinese. Since the ethnicities in some countries such as Brazil are complicated, it is difficult to define the ethnicities in different studies. As shown in [Figure 2](#ijms-16-02403-f002){ref-type="fig"} and [Table 2](#ijms-16-02403-t002){ref-type="table"}, a total of 98 different SNPs were investigated in these studies, which distributed in 23 different exons and the flanking regions of *INSR* gene. We picked the SNPs that were examined in more than three studies for further meta-analysis. The PCOS patients and controls were genotyped for rs1799817 SNP in 12 studies, for rs2059806 in four studies, and for rs2059807 in four studies.

ijms-16-02403-t001_Table 1

###### 

The characteristics of the studies included for qualitative analyses.

  Study                                 Year   Country       Ethnicity   Diagnosis Criteria                                                                                                  Number   Methodology   NOS Score            
  ------------------------------------- ------ ------------- ----------- ------------------------------------------------------------------------------------------------------------------- -------- ------------- -------------------- ---
  Conway \[[@B26-ijms-16-02403]\]       1994   UK            ND          ND                                                                                                                  8        22            SSCP, sequencing     6
  Talbot \[[@B27-ijms-16-02403]\]       1996   UK            ND          Oligo/amenorrhea, hirsuitism, raised testosterone/androstenedione, polycystic ovaries                               5        24            SSCP, sequencing     6
  Siegel \[[@B12-ijms-16-02403]\]       2002   USA           White       Oligomenorrhea, hyperandrogenism, polycystic ovaries                                                                136      99            RFLP                 7
  Chen \[[@B28-ijms-16-02403]\]         2004   China         Chinese     Oligo/amenorrhea, LH/FSH ≥ 2.5 or TT ≥ 1.56 nmol/L, polycystic ovaries, without endocrine disease or hypertension   40       120           RFLP                 8
  Jin \[[@B20-ijms-16-02403]\]          2006   China         Chinese     Rotterdam criteria 2003                                                                                             107      109           SSCP, sequencing     6
  Lee \[[@B29-ijms-16-02403]\]          2008   Korea         Korean      Rotterdam criteria 2003                                                                                             100      134           sequencing           7
  Mukherjee \[[@B30-ijms-16-02403]\]    2009   India         Indian      Rotterdam criteria 2003                                                                                             144      180           sequencing           7
  Unsal \[[@B13-ijms-16-02403]\]        2009   Turkey        Caucasian   Rotterdam criteria 2003                                                                                             50       44            RFLP, sequencing     8
  Hanzu \[[@B21-ijms-16-02403]\]        2010   Romania       ND          Rotterdam criteria 2003                                                                                             111      115           sequencing           7
  Goodarzi \[[@B22-ijms-16-02403]\]     2011   USA           ND          Discover cohort: NIH criteria 1990; replication cohort: Rotterdam criteria 2003                                     3758     801           Taqman assay, GWAS   8
  Chen \[[@B15-ijms-16-02403]\]         2011   China         Chinese     Rotterdam criteria 2003                                                                                             6687     4082          GWAS, LDR            7
  Cirilo \[[@B31-ijms-16-02403]\]       2012   Brazil        Brazian     Rotterdam criteria 2003                                                                                             105      117           RFLP                 6
  Ranjzad \[[@B32-ijms-16-02403]\]      2012   Iran          ND          NIH criteria 1990                                                                                                   181      181           RFLP, sequencing     8
  Shi \[[@B16-ijms-16-02403]\]          2012   China         Chinese     Rotterdam criteria 2003                                                                                             9594     9736          GWAS, LDR            7
  Kashima \[[@B33-ijms-16-02403]\]      2013   Japan         Japanese    Diagnostic criteria of the Japan Society of OBGY 2007                                                               99       61            Taqman assay         7
  Skrgatic \[[@B34-ijms-16-02403]\]     2013   Croatia       Crotian     Rotterdam criteria 2003                                                                                             175      150           Taqman assay         5
  Ramezani \[[@B35-ijms-16-02403]\]     2013   Iran          ND          NIH criteria                                                                                                        156      186           RFLP                 7
  Louwers \[[@B24-ijms-16-02403]\]      2013   Netherlands   ND          Rotterdam criteria 2003                                                                                             2164     703           GWAS                 8
  Grigorescu \[[@B25-ijms-16-02403]\]   2013   Romania       ND          ND                                                                                                                  177      500           KASPar               5
  Yin \[[@B23-ijms-16-02403]\]          2013   China         Chinese     ND                                                                                                                  48       96            ND                   5

ND: not determined; RFLP: restriction fragment length polymorphism analysis; SSCP: sensitive single strand conformation polymorphism analysis; LDR: ligation detection reaction method; GWAS: genome-wide association study; KASPar: fluorescence-based competitive allele-specific PCR.

![Map of investigated *INSR* SNPs in former studies. \*: SNPs that were found to distribute differentially between PCOS and control.](ijms-16-02403-g002){#ijms-16-02403-f002}

ijms-16-02403-t002_Table 2

###### 

Chromosome position and OR/RR of *INSR* SNPs detected in former studies.

  Study                                 SNP            Position            OR/RR (95% CI)                            *p* Value
  ------------------------------------- -------------- ------------------- ----------------------------------------- ---------------------------------------------------
  Conway \[[@B26-ijms-16-02403]\]       rs1799817      7125286             ND                                        ND
  rs1799815                             7125508        ND                  ND                                        
  rs1799816                             7125507        ND                  ND                                        
  Talbot \[[@B27-ijms-16-02403]\]       rs2860178      7170506             ND                                        ND
  rs2860177                             7167940        ND                  ND                                        
  rs2059806                             7166365        ND                  ND                                        
  rs2229429                             7166377        ND                  ND                                        
  rs41509747                            7150480        ND                  ND                                        
  rs2229431                             7141764        ND                  ND                                        
  rs41339753                            7128812        ND                  ND                                        
  rs1799815                             7125508        ND                  ND                                        
  rs1799817                             7125286        ND                  ND                                        
  Siegel \[[@B12-ijms-16-02403]\]       rs1799817 \*   7125286             RR: 2.1 in lean                           0.03 in lean, 0.32 in obese
  Chen \[[@B28-ijms-16-02403]\]         rs1799817 \*   7125286             ND                                        \<0.01 in total and lean, \>0.05 in obese
  Jin \[[@B20-ijms-16-02403]\]          ND             7125522 \*          ND                                        \<0.01
  Lee \[[@B29-ijms-16-02403]\]          ND             7184410             ND                                        ND
  rs6510959                             7184227        1.39 (0.77--2.50)   0.2726                                    
  rs2303672                             7168394        0.82 (0.42--1.62)   0.5707                                    
  rs2059806                             7166365        1.31 (0.86--2.00)   0.2134                                    
  rs2252673                             7150407        0.90 (0.61--1.31)   0.5688                                    
  rs2860175                             7132070        1.46 (0.82--2.62)   0.2010                                    
  rs1799817                             7125286        0.83 (0.56--1.23)   0.3541                                    
  ND                                    7125064        ND                  ND                                        
  rs78312382 \*                         7117415        0.55 (0.32--0.96)   0.0360                                    
  Mukherjee \[[@B30-ijms-16-02403]\]    rs1799817 \*   7125286             ND                                        0.181 in total, 0.004 in lean
  Unsal \[[@B13-ijms-16-02403]\]        rs1799817      7125286             ND                                        0.437
  rs2229434                             7142910        ND                  1                                         
  rs2229430                             7142832        ND                  1                                         
  rs16994210                            7142988        ND                  \>0.05                                    
  rs35045353                            7142927        ND                  \>0.05                                    
  rs2162771                             7142869        ND                  \>0.05                                    
  rs1541806                             7142844        ND                  \>0.05                                    
  rs13306451                            7142813        ND                  \>0.05                                    
  Hanzu \[[@B21-ijms-16-02403]\]        rs2245648      7163219             ND                                        \>0.05
  rs2962                                7163054        ND                  \>0.05                                    
  rs2245649 \*                          7163203        ND                  0.0086                                    
  rs2963 \*                             7163143        2.99 (1.41--6.32)   0.0025                                    
  rs2245655 \*                          7163129        ND                  0.0048                                    
  Goodarzi \[[@B22-ijms-16-02403]\]     rs12459488     7206062             1.11 (0.92--1.34)                         0.3
  rs2971499                             7214271        1.05 (0.86--1.28)   0.067                                     
  rs2252673 \*                          7150407        1.32 (1.08--1.60)   0.006                                     
  rs10401628                            7126207        1.00 (0.80--1.25)   0.99                                      
  rs6510949 \*                          7134391        ND                  0.028                                     
  rs919275                              7261430        ND                  0.089                                     
  rs2042902                             7204459        ND                  0.099                                     
  rs4804404                             7218371        ND                  0.101                                     
  rs7254921                             7278441        ND                  0.111                                     
  rs7258382                             7262558        ND                  0.164                                     
  rs1549616                             7132559        ND                  0.166                                     
  rs7248939                             7268427        ND                  0.190                                     
  rs10408374                            7127283        ND                  0.249                                     
  rs8103483                             7145363        ND                  0.300                                     
  rs4804428                             7235280        ND                  0.360                                     
  rs3745550                             7115562        ND                  0.372                                     
  rs8112883                             7179309        ND                  0.404                                     
  rs10426094                            7205229        ND                  0.420                                     
  rs8110116                             7143700        ND                  0.511                                     
  rs2860172                             7127364        ND                  0.521                                     
  rs7245562                             7218124        ND                  0.522                                     
  rs890862                              7233593        ND                  0.536                                     
  rs10500204                            7182952        ND                  0.544                                     
  rs11668751                            7251831        ND                  0.586                                     
  rs3786680                             7183540        ND                  0.642                                     
  rs11667110                            7136598        ND                  0.644                                     
  rs6510960                             7203721        ND                  0.647                                     
  rs17254521                            7238684        ND                  0.689                                     
  rs4804195                             7254933        ND                  0.947                                     
  rs8111710                             7292572        ND                  0.962                                     
  rs12979424                            7273481        ND                  0.981                                     
  rs10408844                            7244873        ND                  0.992                                     
  rs11880337                            7296441        ND                  ND                                        
  rs6510975                             7266867        ND                  ND                                        
  rs2860183                             7189364        ND                  ND                                        
  Chen \[[@B15-ijms-16-02403]\]         rs1864193      7114202             0.87                                      0.164
  rs11667110                            7136598        0.92                0.343                                     
  rs16990074                            7137340        1.14                0.494                                     
  rs4804304                             7140514        1.18                0.387                                     
  rs2229431                             7141764        1.03                0.832                                     
  rs2229430                             7142832        1.09                0.672                                     
  rs2229434                             7142910        1.05                0.814                                     
  rs2962                                7163054        1.27                0.35                                      
  rs2059807 \*                          7166098        1.34                3 × 10^−4^                                
  rs3815902 \*                          7166127        1.32                0.002                                     
  rs3786681 \*                          7168922        1.34                9 × 10^−4^                                
  rs6510956 \*                          7169265        1.32                0.002                                     
  rs16994298                            7170871        1.26                0.349                                     
  rs8109559                             7171618        1.24                0.159                                     
  rs16994314                            7176963        1.26                0.354                                     
  rs8108622 \*                          7182742        1.5                 7 × 10^−5^                                
  rs10500204 \*                         7182952        1.47                1 × 10^−4^                                
  rs3786680                             7183540        1.21                0.141                                     
  rs891088 \*                           7184751        1.38                4 × 10^−4^                                
  rs17253937 \*                         7184790        1.43                0.001                                     
  rs7245757                             7187617        0.94                0.476                                     
  rs1035939                             7188968        0.93                0.337                                     
  rs4804368                             7190279        0.96                0.602                                     
  rs7254358                             7199330        0.91                0.204                                     
  rs1035942                             7199792        0.93                0.354                                     
  rs8103883                             7203411        1.24                0.075                                     
  rs2042901                             7204383        0.91                0.241                                     
  rs10426094 \*                         7205229        1.34                0.033                                     
  rs12459488                            7206062        0.9                 0.162                                     
  rs3745546 \*                          7211805        1.25                0.036                                     
  rs3745545                             7211830        1.07                0.584                                     
  rs7245562                             7218124        0.93                0.364                                     
  rs7508679                             7222821        0.99                0.879                                     
  rs4804415                             7223808        1.05                0.636                                     
  rs4804416                             7223837        0.97                0.677                                     
  rs7248104                             7224420        0.97                0.643                                     
  rs4804424                             7229666        1.06                0.553                                     
  rs10416429                            7230427        1.03                0.758                                     
  rs890862                              7233593        1.05                0.637                                     
  rs10424224                            7240470        1.03                0.77                                      
  rs10404318                            7247616        0.99                0.944                                     
  rs919275                              7261430        1.09                0.283                                     
  rs8101064                             7293108        1.15                0.273                                     
  Cirilo \[[@B31-ijms-16-02403]\]       rs1799817      7125286             ND                                        \>0.05
  Ranjzad \[[@B32-ijms-16-02403]\]      rs2059806      7166365             ND                                        0.519
  rs1799817                             7125286        ND                  0.630                                     
  Shi \[[@B16-ijms-16-02403]\]          rs2059807 \*   7166098             1.14                                      1.09 × 10^−8^
  Kashima \[[@B33-ijms-16-02403]\]      rs1799817 \*   7125286             ND                                        0.308 in total, 0.037 in lean, 0.644 in obese
  Skrgatic \[[@B34-ijms-16-02403]\]     rs1799817      7125286             ND                                        0.631
  Ramezani \[[@B35-ijms-16-02403]\]     rs1799817      7125286             ND                                        \>0.05
  rs2059806                             7166365        ND                  \>0.05                                    
  Louwers \[[@B24-ijms-16-02403]\]      rs2059807      7166098             0.93                                      0.27
  Grigorescu \[[@B25-ijms-16-02403]\]   rs2059807 \*   7166098             3.1 (1.3--6.8) in non-insulin resistant   \>0.05 in total, \<0.006 in non-insulin resistant
  Yin \[[@B23-ijms-16-02403]\]          ND             7125177 \*          ND                                        0.043
  ND                                    7117386 \*     ND                  0.055 in total, 0.042 in non-fat          
  ND                                    7117367 \*     ND                  0.055 in total, 0.042 in non-fat          

ND: not determined; \*: SNPs that distributed differentially between PCOS and control.

As shown in [Table 1](#ijms-16-02403-t001){ref-type="table"}, three diagnosis criteria of PCOS were used in different studies. NIH criteria include hyperandrogenism and anovulation. The most widely used Rotterdam criteria require PCOS to be diagnosed by at least two of the following three items: oligo-anovulation, hyperandrogensim and PCO. Some studies all three items to be satisfied for the diagnosis of PCO. For rs1799817, five studies adopted Rotterdam criteria, four adopted the criteria including three items, two adopted NIH criteria, and one failed to document the criteria applied. For rs2059806, two studies adopted NIH criteria, one adopted Rotterdam criteria, and one adopted the three-item criteria. For rs2059807, three studies adopted Rotterdam criteria and one failed to document the criteria applied. BMI was not comparable between controls and PCOS cases in the majority of the studies.

2.2. Quality of the Included Studies
------------------------------------

As shown in [Table 1](#ijms-16-02403-t001){ref-type="table"}, the average score of Newcastle-Ottawa quality assessment scale (NOS) was 6.75 (range from 5 to 8). Two items, including the representativeness of the cases and the selection of controls, were the major sources of biases (80%).

2.3. Meta-Analysis Results
--------------------------

For rs1799817 ([Table 3](#ijms-16-02403-t003){ref-type="table"}), a total of 12 studies were collected, including 1158 controls and 1264 PCOS cases. Except two studies in which Hardy-Weinberg Equilibrium (HWE) test could not be conducted due to a lack of information and one study that deviated from HWE \[[@B13-ijms-16-02403]\], genotype distribution in the controls was consistent with HWE. In order to explore the potential correlation between genotypes of rs1799817 and PCOS, we compared every genotype ([Figure 3](#ijms-16-02403-f003){ref-type="fig"}). For CC*vs.* CT, CC*vs.* TT, CT*vs.* TT, CT*vs.* CC + TT, and TT*vs.* CC + CT, no significant association was found, with mild between-study heterogeneity. For CC*vs.* CT + TT, a random effect model was selected due to severe between-study heterogeneity (*p* = 0.06), and no significant association was found (*p* = 0.41).

###### 

Forest plots of meta-analyses on association between rs1799817 frequency and PCOS risk.
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To explore the origin of between-study heterogeneity, subgroup analyses with stratification by ethnicity and weight were carried out ([Figure 4](#ijms-16-02403-f004){ref-type="fig"}). The heterogeneity in the studies from Caucasian population was mild (*p* = 0.62) while the heterogeneity from Asian population was still severe (*p* = 0.002). Both group indicated no significant association (*p* = 0.19 and *p* = 0.62, respectively). Subgroup analyses stratified by weight showed that the heterogeneity in obese population was mild (*p* = 0.78) while in lean population was still severe (*p* = 0.004). The random effect model was selected, and no significant correlation was found (*p* = 0.38 and *p* = 0.62, respectively). Only three studies carried sufficient data to be analyzed in the weight subgroups, and the data was limited to CC*vs.* CT + TT comparison. No correlation was found between rs1799817 and PCOS for CC*vs.* CT + TT, in both lean and obese subgroups. Further analyses indicated no significant difference of BMI between patients with different genotypes (*p* = 0.15). In addition, considering the divergence of diagnostic criteria, we performed the subgroup analysis according to the three diagnostic criteria. Consistent results were obtained from the analyses on groups diagnosed by the same criteria.

###### 

Forest plots of association between genotype frequencies of SNP rs1799817 and PCOS risk. (**A**) Stratified by ethnicity; (**B**) stratified by BMI; (**C**) pooled standardized mean differences of BMI in PCOS patients with different genotypes.
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For rs2059806, four studies including 442 controls and 524 PCOS cases were selected for analyses, ([Table 4](#ijms-16-02403-t004){ref-type="table"}). The between-study heterogeneity was mild and fixed effect model was applied. No significant association between genotype frequencies of rs2059806 and PCOS was found, including GG*vs.* GA, GG*vs.* AA, GA*vs.* AA, GG*vs.* GA + AA, GA*vs.* GG + AA, and AA*vs.* GG + GA ([Figure 5](#ijms-16-02403-f005){ref-type="fig"}).

###### 

Forest plots of association between genotype frequencies of SNP rs2059806 and PCOS risk.

![](ijms-16-02403-g005a)

![](ijms-16-02403-g005b)

Four studies covering 12,830 controls and 11,683 PCOS cases investigated the correlation between rs2059807 genotypes and PCOS. OR of allele C*vs.* allele T was calculated. As shown in [Table 5](#ijms-16-02403-t005){ref-type="table"}, three studies detected significant correlations while one study found no association. All of these studies were performed in large population, and one of them investigated three cohorts \[[@B16-ijms-16-02403]\]. However, pooled OR could not be calculated because the original information provided was insufficient.

ijms-16-02403-t003_Table 3

###### 

Distribution of *INSR* rs1799817 genotype and the allele frequencies for controls and PCOS cases.

  Study                                Year   Country   Age            BMI            Control             PCOS Cases          *p*-Value of HWE                                              
  ------------------------------------ ------ --------- -------------- -------------- ------------------- ------------------- ------------------ -------- ----- ----------- --------- ----- ----------
  Conway \[[@B26-ijms-16-02403]\]      1994   UK        ND             ND             23.8 (21.0--24.7)   32.1 (21.3--46.0)   4/4/0              12/4     8     11/11/0     33/11     22    0.641
  Talbot \[[@B27-ijms-16-02403]\]      1996   UK        28 (25--33)    24 (18--33)    37.2 (30.5--45.8)   36.6 (27.4--47)     4/1/0              9/1      5     12/11/1     35/13     24    0.970
  Siegel \[[@B12-ijms-16-02403]\]      2002   USA       age matched    28 (16--52)    ND                  ND                  93/43              ND       136   62/37       ND        99    ND
  Chen \[[@B28-ijms-16-02403]\]        2004   China     30 ± 4         29 ± 3         23 ± 3              25 ± 4              35/5               ND       40    71/49       ND        120   ND
  Lee \[[@B29-ijms-16-02403]\]         2008   Korea     NDs            ND             20.73 ± 2.36        23.22 ± 3.88        46/40/14           132/68   100   63/59/10    185/79    132   0.554
  Mukherjee \[[@B30-ijms-16-02403]\]   2009   India     24.94 ± 5.46   24.82 ± 5.26   22.16 ± 4.11        25.01 ± 5.63        76/56/12           208/80   144   79/77/24    235/125   180   0.934
  Unsal \[[@B13-ijms-16-02403]\]       2009   Turkey    14.0 ± 3.3     14.5 ± 1.3     20.7 ± 4.2          25.0 ± 5.5          0/29/21            29/71    50    0/22/22     22/66     44    0.015 \*
  Cirilo \[[@B31-ijms-16-02403]\]      2012   Brazil    32.53 ± 6.91   26.09 ± 6.90   25.61 ± 5.48        31.24 ± 7.15        38/20/6            96/32    64    40/22/3     102/28    65    0.411
  Ranjzad \[[@B32-ijms-16-02403]\]     2012   Iran      31.07 ± 5.84   27.13 ± 5.29   25.48 ± 4.21        26.80 ± 6.37        110/63/8           283/79   181   105/64/12   274/88    181   0.964
  Kashima \[[@B33-ijms-16-02403]\]     2013   Japan     34.6 ± 5.3     29.5 ± 3.7     20.8 ± 2.6          23.5 ± 5.2          35/43/21           113/85   99    29/21/11    79/43     61    0.528
  Skrgatic \[[@B34-ijms-16-02403]\]    2013   Croatia   29.1 ± 4.7     26.7 ± 5.9     22.4 ± 3.3          23.4 ± 4.2          115/53/7           283/67   175   95/51/4     241/59    150   0.960
  Ramezani \[[@B35-ijms-16-02403]\]    2013   Iran      30.8 ± 5.6     26.6 ± 5.6     25.5 ± 4.4          26.8 ± 6.4          7/54/95            68/244   156   15/57/114   87/285    186   0.982

\* *p* \< 0.05; ND: not determine; BMI: body mass index.
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###### 

Distribution of the*INSR* rs2059806 genotype and the allele frequencies for controls and PCOS cases.

  Study                               Year   Country   Age            BMI            Control             PCOS              *p*-Value of HWE                                             
  ----------------------------------- ------ --------- -------------- -------------- ------------------- ----------------- ------------------ --------- ----- ---------- -------- ----- -------
  Talbot \[[@B27-ijms-16-02403]\]     1996   UK        28 (25--33)    24 (18--33)    37.2 (30.5--45.8)   36.6 (27.4--47)   3/2/0              8/2       5     14/9/1     37/11    24    0.855
  Lee \[[@B29-ijms-16-02403]\]        2008   Korean    ND             ND             20.73 ± 2.36        23.22 ± 3.88      66/28/6            160/40    100   77/45/11   199/67   133   0.458
  Ranjzad \[[@B32-ijms-16-02403]\]    2012   Iran      31.07 ± 5.84   27.13 ± 5.29   25.48 ± 4.21        26.80 ± 6.37      93/70/18           256/106   181   96/73/12   265/97   181   0.673
  Ramezani \[[@B35-ijms-16-02403]\]   2013   Iran      30.8 ± 5.6     26.6 ± 5.6     25.5 ± 4.4          26.8 ± 6.4        18/58/80           94/218    156   11/76/99   98/274   186   0.344

ND: not determined.
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###### 

Cohort characteristics and odds ratios (ORs) of the *INSR* rs2059807 (C/T).

  Study                                 Year   Country   Title of Cohort   Cases          Age            BMI            OR (95% CI)         *p* Value                                          
  ------------------------------------- ------ --------- ----------------- -------------- -------------- -------------- ------------------- --------------- -------------- ------------------- ---------------
  Chen \[[@B15-ijms-16-02403]\]         2011   China                       895            744            30.68 ± 4.68   28.85 ± 3.62        22.68 ± 3.23    24.55 ± 3.99   1.34 (1.16--1.56)   1.16 × 10^−4^
  Shi \[[@B16-ijms-16-02403]\]          2012   China     GWAS II           2016           1510           53.95 ± 7.18   28.12 ± 2.75        24.93 ± 3.85    24.59 ± 3.17   1.19 (1.07--1.33)   1.66 × 10^−3^
  REP I                                 1913   1908      31.29 ± 5.00      28.01 ± 3.01   22.49 ± 2.17   24.23 ± 3.19   1.16 (1.05--1.28)   4.40 × 10^−3^                                      
  REP II                                5665   6318      29.52 ± 4.75      27.83 ± 3.11   21.95 ± 2.32   23.72 ± 3.18   1.09 (1.02--1.15)   6.61 × 10^−3^                                      
  Louwers \[[@B24-ijms-16-02403]\]      2013   Dutch                       2164           703            ND             29.1 ± 5.73         ND              24.8 ± 5.6     0.93                0.27
  Grigorescu \[[@B25-ijms-16-02403]\]   2013   Romania                     177            500            ND             ND                  ND              27.8 ± 0.35    3.1 (1.3-6.8)       \<0.006

ND: not determined.

2.4. Sensitivity Analysis
-------------------------

Sensitivity analysis was performed by removing one study at one time. For rs1799817, removing any study in the analysis of CC *vs.* CT, CC *vs.* TT, CT *vs.* TT, CC *vs.* CT + TT, CT *vs.* CC + TT, and TT *vs.* CC + CT did not impact the overall results. For rs2059806, when a study from Iran was removed \[[@B32-ijms-16-02403]\], a significant association emerged in the analysis of GG *vs.* GA + AA, with OR 1.57 (1.02--2.42) and *p* = 0.04. No significant association was found from comparison of other genotypes, including GG *vs.* GA, GG *vs.* AA, GA *vs.* AA, GA *vs.* GG + AA, and AA *vs.* GG + GA, in the sensitivity analyses.

2.5. Publication Bias
---------------------

Funnel plots were applied to evaluate the potential publication bias. Visual inspection of the funnel plots indicated no significant asymmetry in analyses for both rs1799817 ([Table S1](#app1-ijms-16-02403){ref-type="app"}) and rs2059806 ([Table S2](#app1-ijms-16-02403){ref-type="app"}). This result indicated the absence of severe publication bias.

3. Discussion
=============

PCOS is associated with diversified genetic and environmental factors. Multiple candidate genes have been reported to increase the risk PCOS, but often the claims could not be confirmed in validation trials. In the past twenty years, a great number of studies were performed, and a dozen SNPs in different regions of *INSR* gene have been implicated in PCOS, but the results were divergent. For example, for rs2252673, a study by Lee*et al.* \[[@B29-ijms-16-02403]\] indicated no association (*p* = 0.5688) while the study by Goodarzi*et al.* \[[@B22-ijms-16-02403]\] reported a significant association (*p* = 0.006). One reason for the discrepancy could be the limited sample sizes and random errors. In this situation, a meta-analysis pooling together all the available data could effectively reduce the bias and achieve a more reliable conclusion.

Among the *INSR* polymorphisms related to PCOS, rs1799817 SNP is the most thoroughly investigated. INSR contains α and β subunits that are encoded by exons 1--11 and exons 12--22, respectively \[[@B36-ijms-16-02403]\]. Exons 17--22 encode the tyrosine kinase domain, and mutations in this region can cause severe insulin resistance and hyperinsulinemia \[[@B37-ijms-16-02403]\]. SNP rs1799817, located in exon 17, was considered to be involved in insulin resistance and PCOS. In the present study, however, we found no significant correlation between the genotypes of rs1799817 and PCOS. It is noteworthy that Ioannidis *et al*. \[[@B14-ijms-16-02403]\] have performed a meta-analysis on rs1799817 and PCOS in 2010 and same result as current one were obtained in that study. A consistent negative result from previous and current studies support that this genetic variation is unlikely involved in the development of PCOS.

Considering that ethnic group possess diversified genetic and environmental backgrounds, and gene-disease associations may vary across these groups \[[@B38-ijms-16-02403]\], we carried out a further subgroup analysis stratified by ethnicity. No significant difference was found in either Asian or Caucasian populations, indicating that the between-study heterogeneity was not mainly originated from population diversity. Again regarding stratification, previous studies indicated that significant association of genotypes with PCOS was not detected in total population, but observed in lean population. Therefore, we applied a subgroup analysis stratified by body mass index (BMI). Our analyses showed no significant correlation in the lean population. Furthermore, no significant difference was detected in the BMI between CC and CT + TT genotypes in PCOS patients. All together, the results suggested that in both lean and obese groups SNP rs1799817 may contribute little or no to the development of PCOS.

SNP rs2059806 located in the exon 8 of *INSR* gene was investigated in three Caucasian cohorts and one Asian cohort. In the present study, we pooled the results from previous studies and found no evidence that rs2039806 represents a predisposition of PCOS. The sensitivity analysis for GG*vs.* GA + AA showed that, when a study from Iran was removed, an association with PCOS arose with a marginal *p* value. It should be pointed out that the positive results are only based on three studies. Further investigation is needed to clarify the impact of this specific genotype on the risk of PCOS.

While many significant SNPs distribute in different exons and flanking regions of *INSR* gene, we noticed that five SNPs involved in the susceptibility of PCOS concentrate in exon 9 and 5\' intron of exon 9, and rs2059807 is one of these SNP located in the "hot spot". A haplotype constructed with four SNPs in this region was demonstrated to be associated with PCOS \[[@B21-ijms-16-02403]\], indicating that this might be a PCOS susceptibility loci. Unfortunately, no pooled OR could be calculated due to the failure to obtain original data from the groups conducted the studies. Nevertheless, rs2059807 should be considered a candidate risk factor for genetic predisposition of PCOS.

This study has several limitations. First, as mentioned above, since we failed to connect with some authors to collect the original data, the power of the subgroup analysis of BMI was compromised, and the pooled OR of rs2059807 could not be calculated; Second, the ethnicity of some countries could not be clearly defined and we had to classify them as the majority. Similarly, cutoff values for lean and obese were somewhat different among different studies, and we accepted the various definitions by individual studies; Third, original studies used various control groups, including healthy women, infertile women, and elderly women, and various diagnostic criteria of PCOS, making it difficult to control the confounding factors.

In conclusion, our meta-analyses summarized the available data concerning the role of *INSR* polymorphisms for genetic predisposition of PCOS. Our results suggested the absence of significant correlation between rs1799817 or rs2059806 SNPs with the development of PCOS, even if ethnicity and BMI were taken into account. However, rs2059807 could be a promising candidate SNP that might be involved in the development of PCOS. Further investigation is required to clarify the role of rs2029807. Since metabolism abnormality is a major contributing factor for the pathogenesis of PCOS, subgrouped analyses according to BMI and/or insulin resistance status may much enhance the study power.

4. Experimental Section
=======================

This meta-analysis was developed according to the PRISM statement. A protocol was registered in PROSPERO, with registration number: CRD42014013145.

4.1. Literature Retrieval
-------------------------

Two authors independently searched the relevant studies published in all languages via 3 databases, including Pubmed, Embase, and Cochrane CENTRAL no later than 7 August 2014. The discrepancies were resolved by discussion. The following keywords were used: (PCOS OR "polycystic ovary syndrome" OR "polycystic ovarian syndrome") AND (INSR OR CD220 OR HHF5 OR "insulin receptor") AND (genotype OR "genetic predisposition" OR SNP OR polymorphism\* OR variant\* OR "genetic susceptibility" OR genetics OR allele). Additionally, we hand-searched the cited references to obtain more relevant studies.

Studies were included in this analysis if: (1) they evaluated the association between *INSR* SNPs and the risk of PCOS; (2) they were case-control or cohort studies; (3) sufficient data were provided to calculate odds ratio (OR) and 95% confidence interval (CI). Studies were excluded if: (1) they were family-association or case series studies; (2) the studies were from the same research group and the studied populations had overlaps. In this case, only the study with largest sample size was included for analysis and the others were excluded.

4.2. Data Extraction
--------------------

The following data was extracted from every study by two reviewers independently, and the discrepancies were resolved by discussion: (1) name of the first author; (2) year of publication; (3) country; (4) ethnicity; (5) age; (6) BMI; (7) diagnosis criteria; (8) methods of genotype; (9) SNP detected; (10) OR; (11) *p* values; and (12) numbers of genotypes in cases and controls. We contacted investigators for additional information when extra information was required. When the SNPs were reported with different nomenclatures, we mapped them on the chromosome and unified them into reference SNP ID numbers.

4.3. Assessment of Study Quality
--------------------------------

The NOS of case control studies was applied to evaluate the quality of studies. Each study was evaluated independently by two authors \[[@B39-ijms-16-02403]\], and they discussed to resolve the disagreement. Three aspects including the selection of population, the comparability of two groups, and the exposure were assessed for eight items, with the highest score of nine.

4.4. Statistical Analysis
-------------------------

HWE was tested by the chi-square method. Review Manager 5.2 (Cochrane Collaboration, Oxford, UK) was used for the meta-analysis. The associations of*INSR* SNPs with PCOS were assessed by calculating the ORs and mean difference among the pooled data, and the statistical significance was calculated with Z test. Q test was employed to assess the between-study heterogeneity. A *p* value higher than 0.1 was considered to be of no serious heterogeneity, and a fixed-effect model (FEM) was subsequently applied to calculate the parameters of the data pool \[[@B40-ijms-16-02403]\]. If the heterogeneity is serious, calculation was carried out based on a random-effect model (REM). To define where the severe heterogeneity come from, subgroup analyses on ethnicity and BMI were executed. Additionally, a sensitivity analysis was performed to verify the stability through removing one individual study a time. Publication bias was evaluated by examining the asymmetry of funnel plot. *p* \< 0.05 was considered to be statistically significant.
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